<DOC>
	<DOCNO>NCT01294709</DOCNO>
	<brief_summary>This study ass safety telcagepant coronary artery disease ( CAD ) participant stable angina exercise treadmill test evaluate whether calcitonin gene-related peptide ( CGRP ) receptor antagonism telcagepant reduces exercise tolerance participant . Primary hypothesis telcagepant significantly decrease exercise duration compare placebo , measure treadmill exercise test ; , true treatment difference exercise duration ( MK-0974 - Placebo ) &gt; = -60 second .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Effects MK-0974 ( Telcagepant ) Exercise Tolerance Patients With Stable Angina ( MK-0974-014 )</brief_title>
	<detailed_description>Amendment 3 protocol reduce dose telcagepant administer single dose 900 mg single dose 600 mg. Pooled data 600-mg 900-mg group wiil utilized analysis . Also due supply issue regard 300 mg telcagepant capsule , 280 mg telcagepant tablet demonstrate bioequivalence 300 mg telcagepant capsule , could administer participant enrolled implementation Amendment 3 .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Inclusion : Participant clinically document stable coronary artery disease demonstrate coronary angiography , echocardiogram , stress test , etc. , participant stable dos current medication treatment coronary artery disease minimum 30 day . Participant history stable angina ( chronic stable angina pectoris trigger physical effort relieve rest and/or sublingual nitroglycerin ) least 3 month prior study start , intervene symptom unstable angina . Participant able demonstrate reproducibly positive exercise test complete treadmill test 2 separate day , within 18 day . Participant agree refrain drink alcohol 24 hour prior study drug administration , study procedure day , release study facility . Participants agree refrain smoke midnight study procedure study procedure complete day . Participant clinically significant abnormality screen laboratory safety assessment . Participant agree refrain unaccustomed strenuous physical activity prestudy ( screen ) visit , throughout study , poststudy visit . Exclusion : Participant pregnant ( positive serum betahuman chorionic gonadotropin [ Î²hCG ] test prestudy ) , breastfeed , female expect conceive within project duration study . Postmenopausal woman currently use hormone replacement therapy exclude participation study . Participant electrocardiogram ( ECG ) finding interfere ECG interpretation may cause false positive stress test ( e.g. , &gt; 1 mm horizontal downsloping STsegment depression rest standard electrocardiographic lead , LownGanongLevine syndrome , WolffParkinsonWhite ( WPW ) , leave bundle branch block ( LBBB ) , leave ventricular hypertrophy ( LVH ) repolarization abnormality , pectus excavatum , ventricular pacemaker , etc. ) . Note : ECG finding may affect stress test result ; may find include may affect test result . These ECG finding exclusion finding may jeopardize interpretation stress test result . Participant heart ratecorrected QT interval ( QTc ) ( Bazett ) &gt; 500 m rest ECG . Participant uncontrolled high blood pressure prestudy screen . Participant baseline heart rate &lt; 40 &gt; 96 beat per minute screening . Participant unstable angina , hypertrophic cardiomyopathy , valvular heart disease , congenital cardiac defect , severe aortic stenosis , class III IV heart failure . Participant diabetes , opinion investigator , unable comply preand postdosing fasting requirement study due risk hypoglycemia . Participant unable withhold acetohexamide , chlorpropamide , glimepride , glimepiride pioglitazone , glimepride rosiglitazone , glipizide , glipizide metformin , glyburide , glyburide metformin , tolazamide , tolbutamide , medication , opinion investigator likely result hypoglycemia within 8 hour dose . Participant myocardial infarction coronary revascularization within prior 2 month . Participant acute myocarditis pericarditis . Participant obese , adipose tissue may interfere ECG interpretation , opinion investigator , whose obesity put participant medical risk . Participant clinically significant hypokalemia hypomagnesemia . Participant history illness , opinion investigator , might confound result study pose additional risk participant participation study . Participant must take follow medication time frame specify : Participant unable refrain anticipates use herbal remedy begin approximately 2 week ( 5 halflives ) prior administration initial dose study drug , throughout study ( include washout interval treatment ) , poststudy visit ; participant unable refrain take drug metabolize cytochrome P450 3A4 ( CYP3A4 ) least 48 hour post dose ( exact length time specific drug metabolize CYP3A4 withhold dependent therapeutic index drug extent metabolize CYP3A4 ) ; participant consumes excessive amount alcohol , opinion investigator , put participant medical risk participate study ( participant clinical [ e.g. , enlarge liver ] laboratory evidence [ e.g. , elevate alanine aminotransferase ( ALT ) ] , chronic alcoholism drug abuse , opinion investigator ) ; participant currently regular user ( include : recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 6 month ; participant take potent CYP3A4 inhibitor , include limited cyclosporine , systemic ( oral/intravenous ) itraconazole , ketoconazole , erythromycin , clarithromycin , telithromycin , nefazodone , human immunodeficiency virus ( HIV ) protease inhibitor within 1 month prior dose MK0974 placebo throughout study period ; participant take moderate CYP3A4 inhibitor , include limited verapamil , diltiazem , fluconazole , fluvoxamine , fluoxetine , aprepitant within 2 week prior dose MK0974 placebo throughout study period ; participant take potent CYP3A4 inducer , include limited rifampicin , rifabutin , carbamazepine , phenytoin , barbiturate , systemic glucocorticoid ( replacement inhale permit ) , nevirapine , efavirenz , pioglitazone , primidone , St. John 's wort within 1 month prior dose MK0974 placebo throughout study period ; participant take triptans , ergot alkaloid within 48 hour prior dose MK0974 placebo throughout study period ; participant take digoxin , medication prolong QTc interval Class IA Class III antiarrhythmic ( quinidine , procainamide , amiodarone , sotalol , etc ) , Seldane ( terfenadine ) , Hismanal ( astemizole ) , Propulsid ( cisapride ) within 1 month prior dose MK0974 placebo throughout study period ; participant receive investigational medication within 4 week prior prestudy ( screen ) visit . Participant history multiple and/or severe allergy , anaphylactic reaction intolerability prescription nonprescription drug food . There concern investigator regard safe participation participant study , reason investigator considers participant inappropriate participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>angina pectoris</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>calcitonin gene-related peptide</keyword>
	<keyword>exercise tolerance ,</keyword>
</DOC>